Clinical trial · no report yet · Phase 2

DETERRED trial: what clinicians have said so far

MPDL3280A With Chemoradiation for Lung Cancer

NCT02525757 ↗
Active, not recruiting
M.D. Anderson Cancer Center
Standard size, estimated: 151–300 verified statements once built

We haven't built an HCP commentary report on DETERRED (atezolizumab plus carboplatin plus paclitaxel in unresectable non-small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on DETERRED so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Indexed so far
15 posts on X, typically up to 66 once built
1 YouTube video, typically up to 4 once built

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: DETERRED: PD-L1 blockadE To Evaluate the Safety of Lung CanceR Therapy Using Carboplatin, Paclitaxel, and Radiation CombinEd With MPDL3280A
Phase: Phase 2
Status: Active, not recruiting
Conditions: Lung Cancer; Non-Small Cell Lung Cancer
Interventions: MPDL3280A; Carboplatin; Paclitaxel; Radiation Therapy
Arms: Group 1: Chemotherapy + Radiation · Experimental
Group 2: MPDL3280A + Chemotherapy + Radiation · Experimental
Enrollment: 52
Primary outcomes: Time to Toxicity
Sponsor: M.D. Anderson Cancer Center with Genentech, Inc.
Start: Jan 26, 2016
Primary completion: Jan 31, 2028 (estimated)
Results posted: No
Registry record: NCT02525757 · updated Jul 16, 2026

Publications

linked from the registry

Augustyn A, Adams DL, He J, Qiao Y, Verma V, Liao Z, Tang CM, Heymach JV, Tsao AS, Lin SH. Giant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With Disease Recurrence and Survival in Non-Small-Cell Lung Cancer Treated With Chemoradiation and Atezolizumab. Clin Lung Cancer. 2021 May;22(3):e451-e465. doi: 10.1016/j.cllc.2020.06.016. Epub 2020 Jun 20. PubMed 32798130

Get this report

Standard

Report, built on orderBuilt within 24 hours of confirming your order: $1,250

Order this report

Quoted on an estimate of the verified statements in the commentary we've indexed so far. Final coverage is set when we build it.You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded.We build it within 24 hours of confirming your order. If we can't build it to our standard, you aren't charged.

Request a free preview

Ask us to build this report. Once it's built, its free preview (summary, finding titles and coverage) is published on this page and we email you the link. The full report is sold separately. Use your work email; we'll send a link to confirm it.

For agents: .json · .md

Indexed commentary on DETERRED so far

Reports on the same drug or indication

The trial

Publications